Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/1999

01-06-1999 | ORIGINAL ARTICLE

Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity

Authors: Katrina L. Mealey, Rola Barhoumi, Robert C. Burghardt, Barry S. McIntyre, Paul W. Sylvester, Howard L. Hosick, Deborah T. Kochevar

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/1999

Login to get access
Metadata
Title
Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity
Authors
Katrina L. Mealey
Rola Barhoumi
Robert C. Burghardt
Barry S. McIntyre
Paul W. Sylvester
Howard L. Hosick
Deborah T. Kochevar
Publication date
01-06-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050960

Other articles of this Issue 2/1999

Cancer Chemotherapy and Pharmacology 2/1999 Go to the issue

ORIGINAL ARTICLE

Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines

ORIGINAL ARTICLE

Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat Enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery

SHORT COMMUNICATION

Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin

SHORT COMMUNICATION

Increased urinary losses of carnitine during ifosfamide chemotherapy

ORIGINAL ARTICLE

Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel

ORIGINAL ARTICLE

Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits